Encouraging news flowed in at
Regeneron Pharmaceuticals Inc.
) from Europe when the European Commission approved eye-drug
Eylea for treating patients suffering from visual impairment due
to macular edema following central retinal vein occlusion (CRVO).
ACTELION LTD (ALIOF): Get Free Report
BAYER A G -ADR (BAYRY): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
REGENERON PHARM (REGN): Free Stock Analysis
To read this article on Zacks.com click here.
Regeneron has co-developed Eylea with the HealthCare unit of
). Regeneron is solely responsible for U.S. sales of the eye
drug. Regeneron and Bayer equally share the profits from ex-U.S
markets. Eylea sales, except for Japan where Regeneron receives a
royalty on net sales.
Eylea is already available in the U.S. for the above indication.
In Sept 2012, the U.S. Food and Drug Administration (FDA)
approved Eylea for the CRVO indication. Eylea was first approved
in the U.S. in late 2011 for treating patients suffering from the
neovascular form of age-related macular degeneration (wet AMD).
Sales of the drug have been on the rise since then.
Sales of Eylea in the U.S. climbed 70% in the second quarter of
2013 to $330 million. Sales in ex-U.S. markets were $96 million,
as reported by partner Bayer. Management is not overly perturbed
by the modest 5.1% sequential growth in Eylea sales in the second
quarter and expects sales to rebound in the coming quarters.
Based on its bullish expectations, the company raised its
forecast for 2013 Eylea sales. Regeneron now expects 2013 sales
of Eylea in the range of $1.3-$1.35 billion (old guidance:
$1.25-$1.325 billion). We expect Regeneron to achieve the
guidance on Eylea. We note that Eylea is also approved for wet
AMD in the EU, Australia, Japan and several other territories.
Regeneron and Bayer are also evaluating Eylea for other
indications such as diabetic macular edema (positive phase III
data presented: approval expected to be sought by year end) and
myopic choroidal neovascularization (phase III). Approval for new
indications would boost the drug's sales potential further.
Regeneron, a biopharmaceutical company, currently carries a Zacks
Rank #3 (Hold). However, biopharma stocks that warrant a look are
Gilead Sciences Inc.
). Both stocks carry a Zacks Rank #1 (Strong Buy).